Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Medtronic
Cipla
Harvard Business School
Express Scripts
Queensland Health
Chinese Patent Office
Deloitte
Argus Health

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 011665

« Back to Dashboard

NDA 011665 describes MESTINON, which is a drug marketed by Valeant Pharm Intl, Valeant Pharms, and Valeant Pharms Llc, and is included in four NDAs. It is available from two suppliers. Additional details are available on the MESTINON profile page.

The generic ingredient in MESTINON is pyridostigmine bromide. There are eleven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the pyridostigmine bromide profile page.
Summary for 011665
Tradename:MESTINON
Applicant:Valeant Pharms Llc
Ingredient:pyridostigmine bromide
Patents:0
Therapeutic Class:Antimyasthenic Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 011665
Mechanism of ActionCholinesterase Inhibitors
Medical Subject Heading (MeSH) Categories for 011665
Suppliers and Packaging for NDA: 011665
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MESTINON pyridostigmine bromide TABLET, EXTENDED RELEASE;ORAL 011665 NDA Valeant Pharmaceuticals North America LLC 0187-3013 N 0187-3013-30
MESTINON pyridostigmine bromide TABLET, EXTENDED RELEASE;ORAL 011665 NDA AUTHORIZED GENERIC Oceanside Pharmaceuticals 68682-301 N 68682-301-30

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength180MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Deloitte
Daiichi Sankyo
Argus Health
Merck
Harvard Business School
Healthtrust
Medtronic
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.